A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male patients, \>/=18 years of age
former smoker (smoked \>/= 100 cigarettes in his lifetime and quit \>12 months before enrollment)
locally advanced (stage IIIb), metastatic (stage IV) or recurrent squamous non-small cell lung cancer
prior platinum-based therapy for advanced NSCLC
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
You may not be if
uncontrolled symptomatic central nervous system (CNS) metastases
prior therapy against epidermal growth factor receptor (EGFR)
\>1 prior chemotherapy for advanced/metastatic NSCLC
radiotherapy \<28 days prior to enrollment
history of melanoma at any time, or another malignancy in the last 5 years except for carcinoma in situ of the cervix, basal or squamous cell carcinoma of the skin, or surgically cured malignant neoplasias with a disease-free interval of \>5 years
not fully treated eye inflammation or infection, or predisposing conditions